Downloadable Slidesets

Share

Program Content

Activities

  • NTRK Fusion Testing
    Rationale for Targeting TRK Fusions in Solid Tumors and Implementing NTRK Gene Testing in the Clinic
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

  • 1<sup>st</sup> Gen TRK Inhibitors
    The Activity and Safety of First-Generation TRK Inhibitors in NTRK Fusion–Positive Cancers
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

  • 2nd Gen TRK Inhibitors
    Overcoming Acquired Resistance With Second-Generation TRK Inhibitors
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

  • <i>EP</i>: NTRK Fusion-Positive Cancer
    ExpressPoints
    Staying on TRK: Addressing Clinical Challenges and Improving Outcomes in NTRK Fusion–Positive Cancers
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2021

    Expires: June 15, 2022

Faculty

cover img faculity

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Alexander E. Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

Theodore Laetsch, MD

Associate Professor
Division of Oncology
Department of Pediatrics
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Supporters

Genentech, a member of the Roche Group